Osteosarcoma

1. Clinical Overview

Summary

Osteosarcoma is the most common primary malignant bone tumour, accounting for approximately 20% of all primary bone cancers and representing the most frequent bone malignancy in children and young adults. It is characterised by the production of osteoid (immature bone matrix) or primitive bone by malignant mesenchymal cells. The disease exhibits a bimodal age distribution: the primary peak occurs in adolescents and young adults (10-25 years) during periods of rapid skeletal growth, with a second smaller peak in older adults (> 60 years), typically arising secondary to Paget's disease of bone or prior radiation exposure. [1,2]

The tumour demonstrates a strong predilection for the metaphyseal regions of long bones, with approximately 75-80% of cases occurring around the knee joint. The distal femur accounts for ~40% of cases, the proximal tibia ~20%, and the proximal humerus ~10%. This anatomical distribution correlates with areas of maximal bone growth during adolescence. [1,3]

Patients typically present with persistent bone pain that characteristically worsens at night and with rest, accompanied by a palpable mass and sometimes reduced range of motion of adjacent joints. Approximately 10% of patients present with a pathological fracture through the tumour. Systemic symptoms such as weight loss and fever are uncommon in early disease but may indicate advanced or metastatic disease. [2,4]

Imaging reveals an aggressive mixed lytic and sclerotic lesion with characteristic periosteal reactions including the sunburst (sunray) pattern and Codman's triangle (elevated periosteum). The diagnosis requires histological confirmation via biopsy, which must be carefully planned by the multidisciplinary team to avoid compromising future surgical margins. [5,6]

Modern treatment follows a trimodal approach: neoadjuvant chemotherapy (pre-operative) → surgical resection with wide margins → adjuvant chemotherapy (post-operative). The standard chemotherapy regimen is MAP: Methotrexate (high-dose), Adriamycin (doxorubicin), and Platin (cisplatin). Limb-sparing surgery is now possible in approximately 80-90% of extremity cases, with amputation reserved for extensive disease or neurovascular compromise. [7,8]

Prognosis is significantly influenced by several factors: presence of metastatic disease at diagnosis, histological response to neoadjuvant chemotherapy (≥90% tumour necrosis indicates good response and better prognosis), tumour location (axial skeleton has worse prognosis than appendicular), and ability to achieve complete surgical resection with wide margins. For localised disease, 5-year survival rates are approximately 60-70% with modern multimodal treatment. For metastatic disease at presentation, 5-year survival drops to 20-30%, though complete resection of lung metastases can improve outcomes. [9,10]

Clinical Pearls

"Knees Know": The vast majority of osteosarcomas (60%) occur around the knee joint – distal femur and proximal tibia. Always consider osteosarcoma in adolescents with persistent knee pain.

"Sunburst + Codman's Triangle": These classic radiographic signs represent aggressive periosteal reaction and are highly suggestive of osteosarcoma, though not pathognomonic.

"Pain at Night = Red Flag": Night pain and rest pain that worsens rather than improves with rest suggests aggressive bone pathology. Simple mechanical pain improves with rest.

"Chemotherapy Response = Prognosis": Histological assessment of tumour necrosis (≥90% = good response, less than 90% = poor response) is the most important prognostic factor for localised disease and guides adjuvant therapy.

"Biopsy Pathway Planning": The biopsy tract becomes contaminated with tumour cells and must be excised en bloc with the definitive resection. Poor biopsy planning can compromise limb salvage options.

"Alkaline Phosphatase Monitoring": Serum alkaline phosphatase (ALP) is elevated in 40-50% of cases at diagnosis and serves as a useful tumour marker for monitoring response and detecting recurrence.

"Growth Spurt Association": Osteosarcoma peaks during adolescent growth spurts, with taller individuals at higher risk. The tumour appears to exploit active bone remodelling processes.

"Skip Lesions Are Critical": Discontinuous tumour deposits in the same bone occur in 1-2% of cases and dramatically alter surgical planning. Full-bone MRI is mandatory.

---

2. Epidemiology

Demographics

Anatomical Location

Risk Factors

Temporal Trends

Recent epidemiological studies demonstrate stable incidence rates over the past three decades despite advances in treatment, suggesting that the fundamental biological drivers of osteosarcoma remain constant. Survival rates have plateaued since the introduction of MAP chemotherapy in the 1980s, highlighting the need for novel therapeutic approaches. [15]

---

3. Classification

Histological Subtypes

Conventional (Intramedullary) Osteosarcoma

Variant Subtypes

Secondary Osteosarcoma

Enneking Surgical Staging System

AJCC TNM Staging (8th Edition)

---

4. Pathophysiology

Cellular Origin

Osteosarcoma arises from primitive mesenchymal cells of bone marrow stroma that exhibit osteoblastic differentiation. The defining histological feature is the production of osteoid (unmineralised bone matrix) or immature bone directly by the malignant cells, distinguishing osteosarcoma from other bone tumours. The malignant cells demonstrate varying degrees of osteoblastic, chondroblastic, or fibroblastic differentiation. [2,3]

Molecular Pathogenesis

Genetic Alterations

Chromosomal Characteristics

• Complex Karyotype: Osteosarcoma typically exhibits marked chromosomal instability with multiple gains, losses, and structural rearrangements. [15]
• Aneuploidy: Abnormal chromosome numbers are nearly universal.
• Chromothripsis: Catastrophic chromosome shattering and reassembly occurs in 25-30% of cases, particularly high-grade tumours. [16]
• No Consistent Translocation: Unlike Ewing sarcoma, osteosarcoma lacks a characteristic chromosomal translocation, reflecting its complex genetic landscape.

Growth Factors and Signalling

Growth and Local Invasion

Osteosarcoma typically arises in the metaphyseal region of long bones, the area of most active bone remodelling during growth. The tumour:

• Destroys normal bone architecture through osteoclast activation and direct invasion.
• Penetrates cortex and elevates periosteum, creating characteristic radiographic signs.
• Forms soft tissue mass extending beyond bone, often infiltrating adjacent muscle compartments.
• May cross growth plate (physis) in advanced cases, though growth plate initially acts as barrier.
• Invades neurovascular structures in aggressive cases, potentially precluding limb salvage.

Metastatic Spread

Haematogenous dissemination is the predominant mode of metastasis:

Micrometastases: Many patients with apparently localised disease have micrometastatic disease (not detectable on imaging), explaining the historical poor outcomes with surgery alone and the dramatic improvement with systemic chemotherapy. The lungs act as the first capillary bed encountered by venous drainage from long bones, accounting for the overwhelming pulmonary tropism. [7,17]

Association with Bone Growth

The peak incidence during the adolescent growth spurt and predilection for metaphyseal regions of fastest-growing bones suggests a strong relationship between rapid bone turnover/remodelling and osteosarcoma development. Large dogs (Great Danes, Rottweilers) also develop osteosarcoma at high rates during their rapid growth phase, supporting this hypothesis. The tumour appears to exploit the cellular machinery of active osteogenesis, with malignant transformation occurring during the proliferative phase of bone formation. [11]

Tumour Microenvironment

The osteosarcoma microenvironment is complex and highly vascular, with extensive bidirectional signalling between tumour cells, osteoclasts, osteoblasts, endothelial cells, and immune cells. Osteosarcoma cells secrete factors that stimulate osteoclast activity, leading to bone resorption and release of growth factors (e.g., TGF-β, IGF-1) that further stimulate tumour growth—a "vicious cycle" of bone destruction and tumour proliferation. [18]

---

5. Clinical Presentation

Timeline of Symptoms

Symptom duration at diagnosis is typically 2-6 months, though patients often attribute initial symptoms to trauma or sports injury, delaying diagnosis. Early recognition of red flags is crucial for timely referral and optimal outcomes. The insidious onset means that by the time clinical presentation prompts investigation, the tumour has typically been growing for several months.

Symptoms

Primary Presenting Symptoms

Systemic Symptoms

Symptoms by Location

Red Flags Requiring Urgent Investigation

Examination Findings

Local Examination

Regional Examination

Systemic Examination

Differential Diagnosis Considerations on Clinical Grounds

Before imaging, consider:

• Trauma/Sports Injury: History of injury, improves with rest, no night pain.
• Growing Pains: Bilateral, evening, no daytime symptoms, self-limiting, younger children (3-12 years).
• Osgood-Schlatter Disease: Tibial tuberosity prominence, related to activity, adolescents, improves with skeletal maturity.
• Osteomyelitis: Fever, systemic upset, acute onset, inflammatory markers elevated, recent bacteraemia.
• Other Bone Tumours: Ewing sarcoma (younger, diaphyseal), chondrosarcoma (older adults, axial).
• Stress Fracture: Overuse history, improves with rest, specific high-risk location.
• Juvenile Idiopathic Arthritis: Joint involvement, systemic features, inflammatory markers.

---

6. Investigations

Initial Investigations

Baseline Blood Tests

Imaging - Local Assessment

Plain Radiographs (X-Ray)

First-line investigation. Two orthogonal views (AP and lateral) of affected bone including joint above and below.

Classic Periosteal Reactions

X-Ray Findings by Subtype

Magnetic Resonance Imaging (MRI)

Gold standard for local staging. MRI of entire bone (including joint above and below) in multiple planes (axial, coronal, sagittal).

Typical MRI Signal Characteristics:

• T1: Low to intermediate signal (depends on osteoid content). Hypointense to muscle.
• T2: High signal (cellular areas, oedema). Low signal (mineralised osteoid, sclerotic areas). Heterogeneous.
• Contrast Enhancement: Heterogeneous enhancement in viable tumour. Non-enhancing areas may represent necrosis, haemorrhage, or cystic change.
• STIR: High signal in tumour and peritumoral oedema. Excellent for detecting skip lesions.

Computed Tomography (CT) - Local

CT less sensitive than MRI for soft tissue and marrow involvement but useful for:

• Cortical Bone Detail: Better delineation of cortical destruction and periosteal reaction.
• Mineralisation Pattern: Assessment of osteoid matrix and calcification. Hounsfield units quantify density.
• Biopsy Planning: Guidance for percutaneous biopsy. Safest trajectory planning.
• Surgical Planning: 3D reconstruction for complex anatomy (pelvis, spine). Virtual surgical simulation.
• Contraindication to MRI: Pacemakers, metallic implants, claustrophobia.

Imaging - Metastatic Staging

Biopsy - Definitive Diagnosis

Biopsy Planning Principles

1. Multidisciplinary Team (MDT) Discussion: Biopsy planned by sarcoma surgeon, radiologist, pathologist BEFORE procedure.
2. Longitudinal Approach: Biopsy tract along axis of limb (not transverse). Must be excisable with tumour.
3. Direct Route: Shortest path to tumour avoiding neurovascular bundles, joints, and unnecessary muscle compartments. Single compartment if possible.
4. Haemostasis: Meticulous haemostasis to prevent haematoma (spreads tumour cells). May use haemostatic agents.
5. No Drain or Superficial Drain: If drain used, exit site in line with biopsy tract (will be excised). Remove within 24 hours.
6. Marking: Tattoo or mark biopsy site for identification during definitive surgery. Metallic clips can be placed.
7. Frozen Section Confirmation: Confirm adequate tissue obtained before closing. Ensure diagnostic sample.

Histopathology

Essential Features:

• Malignant Cells Producing Osteoid: Diagnostic hallmark. Pink/eosinophilic lace-like material between cells.
• Pleomorphic Spindle Cells: High-grade nuclei with hyperchromasia. Increased nuclear:cytoplasmic ratio. Mitotic activity.
• Osteoid Matrix: Eosinophilic, lace-like material between cells. Varies in amount. Unmineralised bone.
• Cartilage or Fibrous Component: May be present depending on subtype (chondroblastic, fibroblastic).
• Necrosis: Areas of tumour necrosis common, especially post-chemotherapy.

Immunohistochemistry:

• Generally not required for typical osteosarcoma with osteoid production.
• May be useful for small cell variant:
  • "Exclude Ewing sarcoma: CD99+, FLI1+"
  • "Exclude lymphoma: CD45/LCA+"
  • "Exclude neuroblastoma: Synaptophysin+, Chromogranin+"
• SATB2: Nuclear staining in osteoblastic tumours (supportive but not specific).
• Osteocalcin: Marks osteoblastic differentiation.

Molecular Testing:

• Not routinely required for diagnosis.
• TP53, RB1 alterations common but not diagnostic.
• No specific translocations (unlike Ewing sarcoma: EWSR1-FLI1).
• May be useful for prognostication and clinical trial eligibility.
• Next-generation sequencing increasingly used to identify targetable mutations.

Baseline Functional Assessments

Staging Investigations Summary

Baseline Staging Protocol:

1. X-Ray of primary site (2 views, including joint above and below).
2. MRI of entire involved bone (primary staging, skip lesions, surgical planning).
3. CT Chest (high-resolution, thin-slice for lung metastases).
4. Bone Scan or PET-CT (skeletal metastases, metabolic activity).
5. Biopsy (histological confirmation—MDT-planned).
6. Baseline Bloods (FBC, U&E, LFTs, ALP, LDH, calcium, phosphate).
7. Echocardiogram and Audiology (baseline cardiac and hearing function).
8. Fertility Counselling (for post-pubertal patients).
9. Pulmonary Function Tests (if extensive chest surgery anticipated for metastases).

---

7. Differential Diagnosis

Primary Bone Tumours

Infection and Inflammation

Metastatic Disease to Bone

Trauma

Algorithmic Approach to Differential Diagnosis

Age:

• less than 10 years: Ewing sarcoma, Langerhans cell histiocytosis, neuroblastoma metastases, infection.
• 10-25 years: Osteosarcoma, Ewing sarcoma, ABC, osteoid osteoma/osteoblastoma.
• 20-40 years: Giant cell tumour, telangiectatic osteosarcoma, lymphoma, fibrous dysplasia.

• 40 years: Chondrosarcoma, metastases, Paget's osteosarcoma, multiple myeloma.

Location:

• Epiphysis: Giant cell tumour, chondroblastoma, clear cell chondrosarcoma.
• Metaphysis: Osteosarcoma, osteomyelitis, aneurysmal bone cyst, non-ossifying fibroma.
• Diaphysis: Ewing sarcoma, fibrous dysplasia, adamantinoma, lymphoma.
• Axial Skeleton: Chondrosarcoma, metastases, multiple myeloma, Ewing sarcoma (pelvis).

Radiographic Pattern:

• Lytic + Sunburst/Codman: Osteosarcoma, Ewing sarcoma (onion-skin more common).
• Purely lytic: Telangiectatic osteosarcoma, Ewing sarcoma, aneurysmal bone cyst, giant cell tumour.
• Sclerotic: Osteoblastic osteosarcoma, osteoid osteoma/osteoblastoma, sclerotic metastases (prostate, breast).
• Cartilage matrix (ring-and-arc): Chondrosarcoma, enchondroma, osteochondroma.

---

8. Management

Modern management of osteosarcoma requires a multidisciplinary team (MDT) approach with multimodal therapy: chemotherapy + surgery. The introduction of chemotherapy in the 1970s transformed prognosis from ~20% 5-year survival (surgery alone) to ~60-70% (combined treatment). This dramatic improvement underscores the importance of addressing micrometastatic disease with systemic therapy. [7,8]

Multidisciplinary Team (MDT)

Core Team Members:

• Orthopaedic Oncologist / Sarcoma Surgeon: Surgical planning and execution. Biopsy coordination.
• Medical Oncologist: Systemic therapy protocols. Toxicity management.
• Paediatric Oncologist: For paediatric/adolescent patients (less than 18 years).
• Radiologist: Imaging staging, response assessment, biopsy guidance.
• Pathologist: Histological diagnosis, response assessment (Huvos grading).
• Radiation Oncologist: Rarely; for unresectable disease or positive margins where re-excision not possible.
• Clinical Nurse Specialist: Coordination, patient support, chemotherapy administration.
• Physiotherapist: Pre- and post-operative rehabilitation. Mobility aids. Gait training.
• Occupational Therapist: Functional assessment, activities of daily living aids.
• Psychologist/Psychiatrist: Psychological support for patient and family. Body image issues. Depression screening.
• Social Worker: Social support, financial assistance, school/work liaison.
• Prosthetist/Orthotist: For amputation or complex reconstruction. Custom prosthetics.
• Palliative Care: For metastatic or progressive disease. Pain management. End-of-life care.
• Genetic Counsellor: For hereditary cancer predisposition syndromes.
• Fertility Specialist: Pre-treatment counselling and preservation.

Treatment Algorithm

SUSPECTED OSTEOSARCOMA
(Persistent bone pain, mass, red flags)
                ↓
────────────────────────────────────
URGENT IMAGING
- X-Ray (2 views)
- If suspicious → Urgent MDT Referral
  (within 2 weeks for suspected bone sarcoma)
────────────────────────────────────
                ↓
SPECIALIST SARCOMA CENTRE
STAGING INVESTIGATIONS
- MRI (primary site, full bone)
- CT Chest (lung metastases)
- Bone Scan or PET-CT (skeletal mets)
- Baseline bloods (ALP, LDH, FBC, U&E, LFTs)
- Cardiac (ECHO) and Hearing (Audiometry) baseline
- Fertility counselling
────────────────────────────────────
                ↓
MDT-PLANNED BIOPSY
- Core needle biopsy (preferred)
- Careful trajectory planning
- Open biopsy if core insufficient
────────────────────────────────────
                ↓
HISTOLOGICAL DIAGNOSIS CONFIRMED
MDT DISCUSSION OF STAGING AND TREATMENT PLAN
                ↓
        ┌───────┴──────┐
  LOCALISED DISEASE   METASTATIC DISEASE
    (M0, ~80-85%)      (M1, ~15-20%)
        ↓                      ↓
────────────────────────────────────
LOCALISED DISEASE PATHWAY
────────────────────────────────────
        ↓
NEOADJUVANT CHEMOTHERAPY
(Pre-operative, 8-12 weeks)
- MAP Protocol: Methotrexate, Adriamycin/Doxorubicin, Cisplatin
- Usually 2-3 cycles
- Aims: Shrink tumour, treat micrometastases, assess response
        ↓
RESPONSE ASSESSMENT
(Week 8-10)
- Imaging (MRI, PET-CT)
- Clinical examination (pain, mass size)
- ALP/LDH trend
        ↓
SURGERY
(Weeks 10-12 from treatment start)
┌─────────────────────┴─────────────────────┐
LIMB-SPARING SURGERY              AMPUTATION
(~80-90% of extremity cases)      (10-20%)
- Wide local excision             - If limb salvage not possible
- Tumour-free margins (≥2 cm)     - Extensive disease
- Reconstruction:                 - Neurovascular encasement
  • Endoprosthesis               - Infection
  • Allograft                    - Patient choice
  • Allograft-prosthesis         - Failed limb salvage
  • Vascularised fibula          - Pathological fracture (relative)
  • Rotationplasty (children)
        ↓
HISTOPATHOLOGICAL RESPONSE ASSESSMENT
(Resection specimen - Huvos grading)
┌────────────────┴────────────────┐
GOOD RESPONSE           POOR RESPONSE
(≥90% necrosis)        (less than 90% necrosis)
Grade III-IV           Grade I-II
~60-80% 5-year survival   ~40-55% 5-year survival
        ↓
ADJUVANT CHEMOTHERAPY
(Post-operative, 18-20 weeks)
- Continue MAP protocol
- If good response: Continue same regimen
- If poor response: Consider intensification (trial)
- Total treatment duration: ~6-9 months
        ↓
SURVEILLANCE
- Regular imaging and clinical review
- Years 1-2: Every 3 months
- Years 3-5: Every 6 months
- Years 5+: Annually
- Long-term survivorship care

────────────────────────────────────
METASTATIC DISEASE PATHWAY
────────────────────────────────────
        ↓
CHEMOTHERAPY
(MAP protocol, full course)
        ↓
RESPONSE ASSESSMENT
(After 2-3 cycles)
        ↓
┌───────────────┴───────────────┐
RESECTABLE DISEASE   UNRESECTABLE DISEASE
        ↓                       ↓
PRIMARY RESECTION      PALLIATIVE CHEMOTHERAPY
+                      +/- Radiotherapy
METASTASECTOMY         (Pain control, local control)
(Pulmonary metastasectomy if less than 5-10 nodules, unilateral or bilateral) +
+                      SUPPORTIVE CARE
ADJUVANT CHEMOTHERAPY  - Pain management
(Complete MAP course)  - Psychosocial support
        ↓              - Symptom control
SURVEILLANCE           - Advanced care planning
(Monitor for recurrence, new metastases) ↓
                       PALLIATIVE CARE

Neoadjuvant (Pre-operative) Chemotherapy

Rationale:

1. Treat Micrometastases: Addresses subclinical metastatic disease early, improving survival.
2. Tumour Shrinkage: May facilitate limb-sparing surgery or reduce surgical morbidity. Improves margin achievability.
3. Response Assessment: Histological response predicts prognosis and guides adjuvant therapy. In-vivo chemosensitivity test.
4. Time for Planning: Allows complex surgical planning, prosthesis manufacturing, and patient psychological preparation.
5. Early Systemic Treatment: Initiates treatment while staging/planning underway. No delay in addressing metastases.

Standard Regimen: MAP Protocol [7,8]

Typical Neoadjuvant Course:

• 2-3 cycles (8-12 weeks total) before surgery.
• Example schedule:
  • "Weeks 1-4: Cycle 1 (Methotrexate weekly x 4, then Doxorubicin and Cisplatin)"
  • "Weeks 5-8: Cycle 2 (repeat)"
  • "Weeks 9-10: Response assessment"
  • "Week 10-12: Surgery"

Alternative/Additional Agents (less commonly used or investigational):

• High-Dose Ifosfamide: May be added in poor-risk patients or poor responders (investigational). Requires mesna uroprotection.
• Etoposide: Sometimes added to MAP (MAPIE regimen).
• Investigational Agents: mTOR inhibitors (everolimus, sirolimus), tyrosine kinase inhibitors (sorafenib), immunotherapy (pembrolizumab for MSI-high tumours—rare in osteosarcoma).

Response Assessment:

• Clinical: Reduction in pain, mass size, improved function.
• Radiological:
  • "MRI: Tumour size, enhancement pattern (reduced enhancement suggests necrosis). [18]"
  • "PET-CT: Reduced FDG uptake (SUVmax reduction > 50% suggests good response). [19]"
• Biochemical: Reduction in ALP, LDH towards normal suggests response.
• Definitive Assessment: Histological response on resection specimen (Huvos grading—see below).

Surgery

Surgery aims for complete tumour resection with wide margins while preserving function where oncologically safe. Margin status is the single most important local control factor—inadequate margins lead to high local recurrence rates (~25-30%) even with chemotherapy. [20]

Principles of Surgical Resection

1. Wide Margins: Tumour-free margins of ≥2 cm in all planes if anatomically possible. Margin adequacy is critical for local control.
   • R0 Resection: Microscopically negative margins (goal).
   • R1 Resection: Microscopically positive margins (inadequate—consider re-excision or adjuvant RT).
   • R2 Resection: Macroscopically positive (gross residual disease—poor prognosis).
2. En Bloc Resection: Tumour, surrounding reactive zone, and entire biopsy tract excised as single specimen without violation of tumour.
3. Preserve Neurovascular Structures: If not involved, carefully preserve major nerves and vessels for limb salvage and function.
4. Functional Reconstruction: Restore skeletal continuity and joint function to allow weight-bearing and activities of daily living.
5. Avoid Contamination: Careful soft tissue handling. Change instruments if tumour exposed. Copious lavage.

Limb-Sparing Surgery (~80-90% of Extremity Cases)

Indications:

• Wide surgical margins achievable (≥2 cm).
• Major neurovascular bundle not involved or can be reconstructed.
• Adequate response to chemotherapy (relative factor—poor response may require wider margins).
• Expected functional outcome acceptable (patient able to use limb post-operatively).
• Patient preference (if oncologically equivalent to amputation).

Contraindications (Favouring Amputation):

• Absolute:
  • Involvement of major neurovascular bundle not reconstructible (e.g., femoral nerve, sciatic nerve—leg not functional without).
  • Extensive soft tissue involvement precluding adequate margins.
  • Pathological fracture with extensive contamination (relative—depends on extent).
  • Active infection at surgical site.
  • Progression on chemotherapy with unresectable disease.
• Relative:
  • Very young children (growth plate issues, limb-length discrepancy > 5 cm anticipated).
  • Poor chemotherapy response with bulky residual disease.
  • Patient preference for amputation (e.g., desire for higher activity level than reconstruction allows).

Reconstruction Options:

Post-operative Rehabilitation:

• Physiotherapy: Starts early (post-op day 1-2). Range of motion exercises. Strengthening. Gait training.
• Weight-bearing: Depends on reconstruction:
  • "Endoprosthesis: Partial weight-bearing 6-12 weeks."
  • "Allograft: Protected weight-bearing 3-6 months (until union)."
  • "Vascularised fibula: Protected weight-bearing 3-4 months (until hypertrophy)."
• Occupational therapy: Activities of daily living. Adaptive equipment.
• Psychosocial support: Body image issues. Depression screening. Return to school/work planning.

Amputation (10-20% of Extremity Cases)

Indications:

• Neurovascular bundle extensively involved (limb non-functional if preserved).
• Inadequate soft tissue coverage for limb-sparing surgery.
• Extensive bone destruction precluding stable reconstruction.
• Pathological fracture with widespread soft tissue contamination.
• Infection complicating limb salvage (salvage attempt failed).
• Failed limb salvage (multiple revisions, chronic infection, non-union, mechanical failure).
• Patient preference after informed consent (some patients prefer amputation for faster rehabilitation or higher activity level).

Levels:

• Lower limb:
  • "Below-knee (transtibial): Preferred if adequate distal tibia/fibula preserved. Better function than above-knee."
  • "Above-knee (transfemoral): If proximal tibia involved. More functional limitation."
  • "Hip disarticulation: If proximal femur involved."
  • "Hemipelvectomy: If pelvic involvement."
• Upper limb:
  • "Below-elbow (transradial): Preferred if forearm spared."
  • "Above-elbow (transhumeral): If humerus involved."
  • "Shoulder disarticulation: If proximal humerus/shoulder involved."
  • "Forequarter (interscapulothoracic): If scapula involved."

Post-amputation Care:

• Prosthetics: Modern prosthetics allow high function. Myoelectric prostheses for upper limb. Microprocessor-controlled knees for lower limb.
• Rehabilitation: Intensive physiotherapy. Gait training. Phantom limb pain management.
• Psychological support: Body image. Depression common. Peer support groups beneficial.
• Functional outcome: Many amputees return to high-level activities including sports.

Axial Skeleton (Pelvis, Spine)

Osteosarcoma of axial skeleton has worse prognosis and more challenging surgery:

• Pelvis: Requires hemipelvectomy (internal or external). Reconstruction difficult. High complication rate.
• Spine: Requires vertebrectomy. Risk of neurological injury. Reconstruction with spinal instrumentation and bone graft/cage. Radiation may be used adjuvant if margins inadequate.

Metastasectomy (Pulmonary)

For patients with resectable lung metastases (present at diagnosis or recurrent):

• Indications:
  • Primary tumour controlled (resected with clear margins).
  • less than 5-10 lung nodules (some centres accept more if unilateral).
  • Metastases surgically accessible.
  • No extrapulmonary metastases.
  • Patient fit for thoracotomy.
• Approach: Thoracotomy (open) allows manual palpation (more sensitive than CT). VATS (video-assisted) possible for peripheral lesions.
• Outcomes: Complete resection of lung metastases improves 5-year survival from ~10-20% to ~30-40%. [9]
• Repeat metastasectomy: If recurrent lung metastases remain resectable, repeat surgery may be beneficial.

Histopathological Response Assessment (Huvos Grading)

After neoadjuvant chemotherapy, the resection specimen is assessed for tumour necrosis. This is the most important prognostic factor for localised disease.

Good response: Grade III-IV (≥90% necrosis). Poor response: Grade I-II (less than 90% necrosis).

Adjuvant (Post-operative) Chemotherapy

Rationale: Continue treating micrometastatic disease. Total chemotherapy duration ~6-9 months (neoadjuvant + adjuvant).

Regimen:

• Good response (≥90% necrosis): Continue same MAP regimen. Standard duration.
• Poor response (less than 90% necrosis): Consider:
  • Continue MAP (standard approach—limited evidence for changing regimen).
  • Intensification with additional agents (ifosfamide, etoposide—investigational, no proven survival benefit).
  • Clinical trial enrollment.

Monitoring During Chemotherapy:

• FBC: Before each cycle. Dose reduction/delay if ANC less than 1.0, platelets less than 75-100.
• Renal function: Before methotrexate and cisplatin. Dose adjust if GFR reduced.
• Liver function: Before methotrexate.
• Cardiac function: ECHO before each doxorubicin dose. Discontinue if EF drops below 50% or > 10% absolute decrease.
• Audiology: Every 2-3 cycles of cisplatin. Switch to carboplatin if significant hearing loss.
• Methotrexate levels: 24h, 48h, 72h post-dose. Prolong leucovorin if delayed clearance.

Radiotherapy

Role is LIMITED in osteosarcoma (radiosensitivity low):

• Indications:
  • Unresectable primary tumour (palliative local control).
  • Positive margins (R1 resection) where re-excision not possible.
  • Axial skeleton (pelvis, spine) where wide margins difficult.
  • Pain palliation in metastatic disease.
• Dose: High dose required (60-70 Gy) due to relative radioresistance. Risk of radiation-induced sarcoma.
• Technique: IMRT (intensity-modulated), proton therapy if available (reduces dose to surrounding tissue).

Novel and Investigational Therapies

• Immunotherapy:
  • "Mifamurtide (muramyl tripeptide): Immune modulator. Approved in Europe (not FDA-approved). Added to MAP, may improve survival in localised disease."
  • "Checkpoint inhibitors (pembrolizumab, nivolumab): Limited efficacy in osteosarcoma (low mutation burden, not typically MSI-high)."
• Targeted Therapy:
  • mTOR inhibitors (sirolimus, everolimus): Under investigation.
  • "IGF-1R inhibitors: Failed phase 3 trials."
  • "Sorafenib (multi-kinase inhibitor): Modest activity in refractory disease."
• CAR-T cells: Targeting HER2, GD2—early phase trials.
• Oncolytic viruses: Under investigation.

---

9. Prognosis and Prognostic Factors

Overall Survival

Prognostic Factors

Favourable Factors

• Localised disease (M0 at diagnosis)
• Good histological response to chemotherapy (≥90% necrosis)
• Extremity location (vs. axial skeleton)
• Distal location (distal femur, tibia vs. proximal femur, pelvis)
• Small tumour size (less than 8 cm)
• Normal alkaline phosphatase at diagnosis
• Complete surgical resection (R0, wide margins)
• Age less than 40 years (vs. older, especially secondary osteosarcoma)

Unfavourable Factors

• Metastatic disease at diagnosis (especially M1b—non-pulmonary metastases)
• Poor histological response (less than 90% necrosis)
• Axial skeleton location (pelvis, spine)
• Large tumour size (> 8 cm)
• Elevated alkaline phosphatase (> 2x ULN)
• Pathological fracture at presentation
• Inadequate surgical margins (R1/R2 resection)
• Secondary osteosarcoma (post-radiation, Paget's disease)
• Age > 60 years

Patterns of Recurrence

• Lung metastases: Most common site of recurrence (~80% of recurrences). Median time to recurrence: 18-24 months. Late recurrences (> 5 years) occur in 5-10%.
• Local recurrence: 5-10% with adequate margins. Up to 25-30% with inadequate margins. Usually within 2-3 years.
• Bone metastases: ~10-15% of recurrences. Often multiple sites. Poor prognosis.

Survivorship Issues

Long-term survivors face multiple late effects:

• Chemotherapy-related:
  • "Cardiac: Anthracycline cardiomyopathy (may manifest 10-20 years post-treatment). Lifelong cardiac monitoring required."
  • "Hearing: Cisplatin-induced hearing loss (permanent). Hearing aids may be required."
  • "Renal: Chronic kidney disease from cisplatin."
  • "Fertility: Azoospermia/premature ovarian failure in 30-50% (alkylating agents, cisplatin)."
  • "Secondary malignancies: Increased risk (5-10 fold) of secondary cancers (leukaemia, solid tumours)."
• Surgery-related:
  • "Prosthesis complications: Revision surgery common (50-60% require revision within 10 years)."
  • "Limb-length discrepancy: In children, requires expandable prosthesis or multiple lengthening procedures."
  • "Chronic pain: Phantom limb pain (amputation), prosthetic pain."
  • "Functional limitation: Reduced range of motion, strength, endurance."
  • "Psychological: Body image, depression, anxiety (30-40% of survivors)."

---

10. Complications

Chemotherapy Complications

Surgical Complications

---

11. Follow-up and Surveillance

Surveillance Protocol

Years 1-2 (Highest risk period):

• Clinical examination: Every 3 months
• Chest CT: Every 3 months (85% of recurrences are pulmonary)
• Plain X-rays of primary site: Every 3 months
• MRI of primary site: Every 6 months (for limb-sparing surgery—assess local recurrence and prosthesis/reconstruction)
• Alkaline phosphatase (ALP), LDH: Every 3 months

Years 3-5:

• Clinical examination: Every 4-6 months
• Chest CT: Every 6 months
• Plain X-rays of primary site: Every 6 months
• MRI of primary site: Every 12 months
• ALP, LDH: Every 6 months

Years 5+:

• Clinical examination: Annually
• Chest CT: Annually (up to 10 years—late recurrences occur)
• Plain X-rays of primary site: Annually
• MRI of primary site: As needed for symptoms
• ALP, LDH: Annually

Additional Surveillance:

• Cardiac function (ECHO): Annually lifelong (anthracycline cardiotoxicity can manifest decades later)
• Audiology: Every 1-2 years (if cisplatin-induced hearing loss)
• Renal function: Annually (cisplatin nephrotoxicity)
• Endocrine function: If hypothalamic-pituitary axis irradiation (rare in osteosarcoma)
• Prosthesis surveillance: Annual X-rays to detect loosening, wear, fracture

Management of Recurrence

Pulmonary Recurrence:

• Resectable (less than 5-10 nodules, no extrapulmonary disease): Metastasectomy + chemotherapy (2nd-line regimen if progression on MAP).
• Unresectable: Palliative chemotherapy. Clinical trial. Best supportive care.

Local Recurrence:

• Resectable: Re-excision with wide margins (may require amputation if limb-sparing initially). Adjuvant chemotherapy.
• Unresectable: Radiotherapy (palliative). Chemotherapy. Best supportive care.

2nd-line Chemotherapy:

• High-dose ifosfamide + etoposide
• Gemcitabine + docetaxel
• Sorafenib (multi-kinase inhibitor)
• Clinical trials (immunotherapy, targeted agents)

---

12. Special Populations and Considerations

Paediatric and Adolescent Patients

Osteosarcoma predominantly affects children and adolescents (75% of cases), requiring special considerations:

Growth-Related Issues

Limb-Length Discrepancy:

• Major concern in skeletally immature patients undergoing limb-sparing surgery.
• Expandable Prostheses: Non-invasive lengthening devices (e.g., STANMORE expandable prosthesis) allow periodic lengthening (every 3-6 months) to match contralateral limb growth.
  • Lengthening achieved via external magnetic device (no surgery required).
  • Can accommodate 8-12 cm of growth typically.
  • Mechanical failure rates higher than fixed prostheses (~20-30% at 5 years).
• Allograft Options: May remodel and grow to some extent in young children, though less predictable.
• Epiphysiodesis: Contralateral limb growth arrest (stapling/ablation of physis) to equalize length if large discrepancy anticipated.
• Shoe Lift: For minor discrepancies (less than 2-3 cm) at skeletal maturity.

Rotationplasty Advantages:

• Preserves growth potential (proximal femoral physis).
• Excellent function (superior to above-knee amputation).
• High activity level possible (running, jumping, sports).
• Challenge: Body image concerns during adolescence—requires extensive counselling, ideally with peer support/previous rotationplasty patients.

Educational and Psychosocial Support

• School Liaison: Maintain education during prolonged treatment (6-9 months). Home tutoring, online learning.
• Peer Relationships: Social isolation risk during treatment. Peer support groups beneficial.
• Late Effects Counselling: Survivors at risk for secondary malignancies, infertility, cardiac disease—lifelong surveillance needed.
• Transition to Adult Care: Structured transition at 16-18 years from paediatric to adult oncology services.

Older Adults (> 60 Years)

Secondary osteosarcoma in older adults has distinct features:

Aetiology

• Paget's Disease: Most common predisposing factor. Malignant transformation in less than 1% of Paget's patients.
  • "Presentation: Change in pain pattern in known Paget's disease. New mass. Pathological fracture."
  • "Sites: Polyostotic Paget's—pelvis, femur, skull."
  • "Prognosis: Very poor (5-year survival less than 10%). Often unresectable due to location and comorbidities."
• Radiation-Induced: Prior radiation therapy (typically > 30 Gy) 10-20 years earlier for breast cancer, lymphoma, prostate cancer.
  • "Latency: Mean 12-16 years post-radiation."
  • "Prognosis: Poor (similar to Paget's osteosarcoma). Often high-grade."

Treatment Challenges

• Comorbidities: Cardiac, renal, hepatic dysfunction limit chemotherapy tolerance.
• Reduced Chemotherapy Tolerance: Dose reductions common (30-50% receive less than 75% planned dose). Higher toxicity rates.
• Surgical Risk: Higher peri-operative morbidity/mortality (5-10% vs. 1-2% in young patients).
• Functional Demands: Lower—may favour less aggressive reconstruction or amputation for faster recovery.

Outcomes

• Survival: Significantly worse than younger patients (5-year survival ~20-30% for localised disease vs. 60-70% in adolescents).
• Quality of Life Focus: Palliative intent more common. Emphasize pain control, function preservation, avoiding prolonged hospitalization.

Pregnant Patients

Rare but important considerations:

• Diagnosis: Avoid radiation-based imaging (X-ray, CT, bone scan). MRI preferred for staging (no ionizing radiation).
• Chemotherapy Timing:
  • "1st Trimester: Highest teratogenicity risk. Consider pregnancy termination if early pregnancy + osteosarcoma requiring immediate chemotherapy."
  • "2nd/3rd Trimester: Chemotherapy possible (especially doxorubicin, cisplatin after 1st trimester). Methotrexate contraindicated (folate antagonist—neural tube defects)."
• Delivery: Planned delivery at 32-34 weeks if possible to allow prompt post-partum chemotherapy.
• Breastfeeding: Contraindicated during chemotherapy (drug excretion in breast milk).

Hereditary Cancer Syndromes

Patients with germline predisposition syndromes require modified surveillance and management:

Li-Fraumeni Syndrome (TP53 Germline Mutation)

• Risk: 15-20 fold increased osteosarcoma risk. Multiple primary cancers (breast, brain, adrenal, sarcomas).
• Surveillance: Whole-body MRI annually from childhood. Avoid ionizing radiation (CT scans, radiation therapy) to minimize secondary malignancy risk.
• Treatment Modifications: Avoid radiotherapy if possible (high secondary malignancy risk). Consider proton therapy if RT essential (lower scatter dose).
• Family Screening: Test first-degree relatives. Genetic counselling mandatory.

Hereditary Retinoblastoma (RB1 Germline Mutation)

• Risk: 500-1000 fold increased osteosarcoma risk, especially if radiation therapy for retinoblastoma.
• Latency: Median 10-15 years post-retinoblastoma diagnosis.
• Surveillance: Annual skeletal survey or whole-body MRI. Low threshold for investigating bone pain.
• Radiation Avoidance: Avoid radiation therapy if possible (further increases osteosarcoma risk).

---

13. Quality of Life and Survivorship

Functional Outcomes

Limb Function

Limb-Sparing Surgery:

• Objective Function: MSTS (Musculoskeletal Tumor Society) score typically 60-80% (vs. 30 = maximum function).
  • "Pain: Mild or intermittent in 60-70%."
  • "Function: Independent ambulation in 80-90%. Return to work/school 70-80%."
  • "Range of Motion: 50-70% of normal for reconstructed joint."
  • "Strength: 60-80% of contralateral limb."
  • "Stability: Good with modern prostheses/reconstructions."
• Limitations: Inability to run, jump, or perform high-impact activities in most. Sports participation limited to low-impact (swimming, cycling).
• Satisfaction: 70-80% of patients satisfied with limb-sparing outcome at 2-5 years.

Amputation:

• Objective Function: MSTS score 50-70% (lower than limb-sparing for lower limb, similar or better for upper limb).
• Prosthetic Use: 80-90% regular prosthetic users. Modern prosthetics allow high function.
• Activity Level: Many amputees achieve higher activity levels than limb-sparing patients (running prostheses, adaptive sports).
• Satisfaction: 60-70% satisfied. Body image concerns persist in 30-40%.

Rotationplasty:

• Objective Function: MSTS score 80-90% (highest functional scores).
• Activity: Unrestricted in most. Running, jumping, sports participation common.
• Satisfaction: 80-90% satisfied functionally. Body image acceptance variable (50-70% fully accepting).

Upper Limb Considerations

• Shoulder: Significant functional loss common (difficulty with overhead activities, heavy lifting). Reverse shoulder arthroplasty improves function if cuff absent.
• Elbow: Hinged prostheses functional for activities of daily living. Limited strength and range.
• Hand/Wrist: Rare primary site but devastating functional loss if required. Prosthetics less functional than lower limb.

Psychological Outcomes

Common Issues (30-50% of survivors):

• Depression: 20-30% experience major depressive episode during or post-treatment.
• Anxiety: 25-35% report significant anxiety (health anxiety, fear of recurrence most common).
• Post-Traumatic Stress: 10-15% meet PTSD criteria related to diagnosis/treatment.
• Body Image Disturbance: 40-60%, especially adolescents and young adults. Worse with amputation and visible scarring.
• Survivor Guilt: Common if treated on ward with patients who succumbed to disease.

Protective Factors:

• Social Support: Strong family/peer support reduces psychological morbidity.
• Peer Support Groups: Engagement with other survivors beneficial.
• Return to Normal Activities: School/work return predicts better psychological outcomes.
• Psychological Therapy: CBT (cognitive-behavioural therapy) effective for depression, anxiety, body image concerns.

Late Effects Surveillance

Survivors require lifelong monitoring for treatment-related complications:

Cardiovascular

• Anthracycline Cardiomyopathy:
  • Risk increases with cumulative dose (> 300 mg/m² doxorubicin).
  • May manifest 10-30 years post-treatment (median 7-10 years).
  • "Surveillance: Annual ECG and echocardiogram lifelong. Consider cardiac MRI if abnormal ECHO."
  • "Management: ACE inhibitors, beta-blockers if early dysfunction. Heart failure management if overt cardiomyopathy."
  • "Lifestyle: Counsel re: exercise (moderate intensity), avoid excessive alcohol, control cardiovascular risk factors."

Renal

• Cisplatin Nephropathy:
  • Chronic kidney disease in 10-20% of long-term survivors.
  • "Surveillance: Annual creatinine, GFR, urinalysis, blood pressure."
  • "Management: Nephrology referral if GFR less than 60. Avoid nephrotoxic drugs (NSAIDs, aminoglycosides). Control hypertension."

Auditory

• Cisplatin Ototoxicity:
  • Permanent high-frequency sensorineural hearing loss in 40-60%.
  • Tinnitus in 20-30%.
  • "Impact: Difficulty hearing in noisy environments, speech discrimination problems, social isolation."
  • "Surveillance: Audiometry every 1-2 years."
  • "Management: Hearing aids. Tinnitus therapy (sound therapy, CBT). Occupational accommodations."

Fertility and Reproductive Health

• Males:
  • Azoospermia/oligospermia in 30-50% post-treatment (alkylating agents, cisplatin most gonadotoxic).
  • "Sperm Banking: Offer before treatment. Success rates for post-pubertal males 80-90%."
  • "Surveillance: Semen analysis 1-2 years post-treatment. Testosterone levels if symptoms of hypogonadism."
  • "Options if Infertile: Assisted reproduction (ICSI if oligospermic), donor sperm, adoption."
• Females:
  • Premature ovarian insufficiency in 30-40% (dose-dependent).
  • "Fertility Preservation: Oocyte/embryo cryopreservation before treatment (requires ovarian stimulation—delays treatment ~2 weeks). Ovarian tissue cryopreservation (experimental)."
  • "Surveillance: Menstrual history, FSH/LH/estradiol if amenorrhoeic."
  • "Management: Hormone replacement therapy for premature menopause. Assisted reproduction (IVF with cryopreserved oocytes/embryos)."

Secondary Malignancies

• Risk: 5-10 fold increased vs. general population.
• Types:
  • "Acute Myeloid Leukaemia (AML): Risk 1-2% at 10 years (alkylating agents, etoposide). Peaks at 2-5 years post-treatment."
  • "Solid Tumours: Breast, thyroid, lung, soft tissue sarcomas. Latency 10-30 years. Radiation field if RT given."
• Surveillance: Age-appropriate cancer screening (mammography, colonoscopy) starting earlier than general population. Annual physical examination. Low threshold for investigating new symptoms.

Socioeconomic Impact

• Employment: 70-80% of survivors return to employment, though 20-30% report discrimination or difficulty obtaining work.
• Education: School/university completion rates lower than general population (~10-15% lower) due to treatment interruptions and late effects.
• Insurance: Difficulty obtaining life/health insurance (cancer history). Genetic discrimination concerns if hereditary syndrome.
• Financial Toxicity: Out-of-pocket costs for prosthetics, revisions, therapies. Estimated $50,000-$200,000 lifetime costs for endoprosthesis revisions alone.

---

14. Future Directions and Research

Novel Therapeutic Approaches

Immunotherapy

• Checkpoint Inhibitors: Limited efficacy in unselected osteosarcoma (low mutation burden, immunologically "cold"). Pembrolizumab/nivolumab responses less than 10%.
  • "MSI-High Tumours: Rare in osteosarcoma but may respond to checkpoint inhibitors."
• Adoptive Cell Therapy:
  • "CAR-T Cells: Targeting HER2, GD2, B7-H3—early phase trials show feasibility but limited efficacy."
  • "Tumour-Infiltrating Lymphocytes (TILs): Expansion and re-infusion under investigation."
• Oncolytic Viruses: Preferentially replicate in cancer cells. HSV-1, adenovirus trials ongoing.
• Immune Combinations: Checkpoint inhibitors + chemotherapy, targeted agents, or other immunotherapies to overcome resistance.

Targeted Therapies

• mTOR Inhibitors: Sirolimus, everolimus—modest single-agent activity. Combinations under investigation.
• IGF-1R Inhibitors: Failed phase 3 trials despite promising preclinical data. Not currently recommended.
• Multi-Kinase Inhibitors: Sorafenib, regorafenib—modest activity in refractory disease. Approved in some countries for advanced osteosarcoma.
• CDK4/6 Inhibitors: Palbociclib for tumours with MDM2/CDK4 amplification (parosteal subtype).
• PARP Inhibitors: For tumours with DNA repair defects (rare).

Novel Chemotherapy Strategies

• Dose Intensification: High-dose chemotherapy with stem cell rescue—no survival benefit in trials.
• Metronomic Chemotherapy: Low-dose continuous chemotherapy (anti-angiogenic effect)—under investigation for maintenance/refractory disease.
• Aerosol Chemotherapy: Inhaled cisplatin for lung metastases—early trials show feasibility.

Precision Medicine

• Molecular Profiling: Next-generation sequencing to identify targetable mutations (currently actionable in less than 10% of cases).
• Circulating Tumour DNA (ctDNA): Blood-based monitoring for minimal residual disease and early recurrence detection—experimental.
• Patient-Derived Xenografts (PDX): Growing patient tumours in mice to test drug sensitivities—personalized therapy selection.

Biomarkers

• Predictive Biomarkers: Identify who will respond to chemotherapy—none validated for clinical use.
• Prognostic Biomarkers: Beyond Huvos grading—circulating microRNAs, gene expression signatures under investigation.

Surgical Innovation

• 3D-Printed Implants: Custom prostheses for complex anatomy (pelvis). Porous surfaces promote bone ingrowth.
• Composite Reconstructions: Combining allograft, autograft, and prosthetic components for optimal function.
• Vascularised Composite Allotransplantation (VCA): Limb transplantation for unsalvageable limbs—rare, experimental.

Survivorship Research

• Late Effects Mitigation: Cardioprotective strategies (dexrazoxane), otoprotection (sodium thiosulfate for cisplatin).
• Quality of Life: Patient-reported outcome measures to guide treatment decisions.
• Psychosocial Interventions: Optimizing psychological support, return to function.

---

15. Multidisciplinary Care Coordination

Pre-Treatment Phase

Diagnosis to Treatment Start (Target: less than 4 weeks):

1. Week 1: Imaging, biopsy planning, MDT discussion
2. Week 2: Biopsy, histology confirmation
3. Week 3: Staging complete, fertility preservation, baseline assessments
4. Week 4: Chemotherapy starts

Key Coordination Points:

• Biopsy Scheduling: Coordinate with surgery, radiology, pathology to minimize delays.
• Fertility Preservation: Urgent referral if desired (delays treatment ~1-2 weeks for females requiring ovarian stimulation).
• Dental Clearance: Extract/repair diseased teeth before chemotherapy (prevent neutropenic sepsis).
• Central Venous Access: PICC line or port placement before chemotherapy start.

During Active Treatment Phase

Chemotherapy Coordination:

• Inpatient vs. Outpatient: High-dose methotrexate requires 3-5 day admission (hydration, leucovorin rescue, monitoring). Doxorubicin and cisplatin may be outpatient (day unit) or short admission.
• Dose Modifications: Real-time discussion between oncology, pharmacy, nursing re: toxicity-driven modifications.
• Supportive Care: Anti-emetics, G-CSF, transfusions coordinated by clinical nurse specialist.

Surgical Coordination:

• Prosthesis Manufacturing: Custom implants require 4-6 weeks (coordinate with surgery date). Modular systems available off-shelf.
• Pre-Operative Optimization: Physiotherapy (strengthen surrounding muscles), occupational therapy (home modifications).
• Blood Products: Cross-match, reserve units (large resections may require 2-6 units).

Rehabilitation Coordination:

• In-Hospital: Early mobilization post-op day 1-2. Physiotherapy twice daily.
• Outpatient: 3-5 sessions/week for 3-6 months post-surgery.
• Prosthetics: Fitting at 6-8 weeks post-amputation. Gait training 3-6 months.

Survivorship Phase

Long-Term Follow-Up Coordination:

• Primary Care: GP liaison for non-oncology health needs. Shared care model after 5 years.
• Late Effects Clinic: Specialized survivorship clinics monitor cardiac, renal, endocrine, psychological late effects.
• Transition: Adolescents transition from paediatric to adult services at 16-18 years (structured handover).

Prosthesis/Reconstruction Surveillance:

• Orthopaedic Oncology Follow-Up: Annual review of implant integrity, function.
• Revision Surgery: Planned revisions for aseptic loosening, fracture, infection—coordinated with oncology (ensure no active disease before major surgery).

---

16. Patient Resources and Support

Professional Organizations

• Bone Cancer Research Trust (BCRT): UK charity. Research funding, patient support, information resources.
• Sarcoma UK: Patient information, support groups, advocacy.
• American Cancer Society (ACS): Comprehensive cancer information, support programs.
• National Cancer Institute (NCI): Research updates, clinical trial database.
• Liddy Shriver Sarcoma Initiative: Patient advocacy, research awareness, survivorship resources.

Support Services

Psychological Support:

• Hospital-based psycho-oncology services.
• Independent counselling charities (Macmillan, Maggie's Centres in UK).
• Peer support groups (in-person and online).
• Mental health crisis lines (24/7 support).

Financial Support:

• Benefits/Insurance: Social worker assistance with disability claims, insurance appeals.
• Charitable Grants: Hardship funds for treatment-related expenses (travel, accommodation, prosthetics).
• Employment Rights: Legal protections against discrimination. Occupational health liaison for workplace accommodations.

Practical Support:

• Transportation: Hospital volunteer drivers, charitable transport services.
• Accommodation: Ronald McDonald House, hospital-linked accommodation for families travelling for treatment.
• Childcare/Eldercare: Respite care during admissions.

Educational Resources

Reliable Online Resources:

• BCRT Osteosarcoma Information Pack (evidence-based, patient-friendly).
• Sarcoma UK Information Sheets (diagnosis, treatment, follow-up).
• Macmillan Cancer Support (UK)—comprehensive guides.
• NCI Osteosarcoma PDQ (Patient and Physician versions).

Avoid:

• Unregulated online forums with anecdotal treatment claims.
• Commercial sites promoting unproven therapies.

Clinical Trials

Finding Trials:

• ClinicalTrials.gov (USA): Comprehensive database. Search "osteosarcoma" + location/age.
• UK Clinical Trials Gateway (UKCTG): NHS-supported trials.
• Cancer Research UK: Trial finder tool.
• MDT Discussion: Oncology team will propose relevant trials.

Considerations:

• Phase 1: First-in-human. Primarily safety testing. Response rates low (less than 10%).
• Phase 2: Efficacy testing in small cohort. Response rates 10-30% typical.
• Phase 3: Randomized controlled trial. Standard therapy ± experimental. May offer best chance of cure if novel agent effective.
• Risk-Benefit: Discuss thoroughly. Trials offer access to cutting-edge therapy but may involve additional monitoring, travel, unknown risks.

Advocacy and Awareness

Patient Advocacy:

• Share experiences to raise awareness (if comfortable—social media, patient stories, fundraising).
• Participate in research (patient representatives on trial committees, steering groups).
• Support rare cancer research (donations, fundraising events).

Awareness Campaigns:

• Sarcoma Awareness Month (July): Educational events, fundraising.
• Bone Cancer Awareness Week: BCRT-led initiative.

---

17. Summary: Key Take-Home Messages

For Clinicians

1. High Index of Suspicion: Persistent bone pain in adolescents (especially night pain, rest pain) warrants X-ray within 2-4 weeks.
2. Biopsy Planning is Critical: Poorly planned biopsy compromises limb salvage. Refer to specialist sarcoma centre before biopsy.
3. Multimodal Therapy is Standard: Chemotherapy (MAP protocol) + surgery. Surgery alone is insufficient (cures less than 20%).
4. Histological Response Predicts Outcome: ≥90% necrosis (good response) → 70-80% 5-year survival. less than 90% necrosis (poor response) → 40-55% 5-year survival.
5. Margins Matter: R0 resection (clear margins) essential for local control. Positive margins → re-excision or radiation therapy.
6. Limb Salvage is Standard: 80-90% of extremity cases. Amputation reserved for extensive disease or neurovascular involvement.
7. Survivorship Surveillance: Lifelong—cardiac (anthracyclines), renal (cisplatin), hearing (cisplatin), secondary malignancies.

For Patients/Families

1. Osteosarcoma is Treatable: 60-70% of patients with localised disease are cured with modern therapy.
2. Treatment is Intensive: 6-9 months chemotherapy + major surgery. Requires commitment but offers best cure chance.
3. Limb Salvage is Usually Possible: 80-90% avoid amputation. Prosthetic reconstructions allow good function.
4. Fertility Preservation: Discuss before treatment starts. Options available (sperm/egg banking).
5. Late Effects are Common: Long-term monitoring essential (heart, kidneys, hearing, secondary cancers).
6. Psychosocial Support is Important: Depression, anxiety common. Seek help early (counselling, peer support).
7. Clinical Trials May be Beneficial: Discuss with oncology team. May offer access to novel therapies.

For Examinations (MRCP, MRCS, FRCS Orth, FRACS)

High-Yield Viva Topics:

1. Radiographic Features: Sunburst pattern, Codman's triangle—describe and explain pathophysiology.
2. Biopsy Principles: Longitudinal trajectory, avoid neurovascular bundles, entire tract excised en bloc with tumour.
3. MAP Protocol: Methotrexate, Adriamycin (doxorubicin), Platinum (cisplatin)—know mechanism, toxicity, monitoring.
4. Huvos Grading: Grade I-IV (necrosis %), good response ≥90%, prognostic significance.
5. Limb-Sparing Options: Endoprosthesis vs. allograft vs. APC vs. vascularised fibula vs. rotationplasty—advantages, disadvantages, indications.
6. Amputation Indications: Neurovascular involvement, extensive soft tissue, infection, patient choice.
7. Metastasectomy: Pulmonary metastases—resection if less than 5-10 nodules, improves survival 10-20% → 30-40%.
8. Differential Diagnosis: Age (Ewing less than 10 years, osteosarcoma 10-25, chondrosarcoma > 40), location (epiphysis → GCT, metaphysis → osteosarcoma, diaphysis → Ewing), X-ray (sunburst → osteosarcoma, onion-skin → Ewing, ring-and-arc → chondrosarcoma).

Key Statistics to Memorize:

• Incidence: 3-4 per million per year (general population), 5.6 per million (adolescents).
• 5-year survival: 60-70% (localised), 20-30% (metastatic).
• Metastatic at presentation: 15-20% (lungs 80% of metastases).
• Limb-sparing rate: 80-90% (extremity cases).
• Elevated ALP: 40-50% at diagnosis.
• Skip lesions: 1-2% (critical to identify—full-bone MRI).

---

References

1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531-1543. PMID: 19197972

2. Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21 Suppl 7:vii320-vii325. PMID: 20943636

3. Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14(11):722-735. PMID: 25319867

4. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523-532. PMID: 24345772

5. Murphey MD, Robbin MR, McRae GA, Flemming DJ, Temple HT, Kransdorf MJ. The many faces of osteosarcoma. Radiographics. 1997;17(5):1205-1231. PMID: 9308109

6. Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2007;2:6. PMID: 17274822

7. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival. J Clin Oncol. 2008;26(4):633-638. PMID: 18235123

8. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776-790. PMID: 11821461

9. Kager L, Zoubek A, Pötschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2003;21(10):2011-2018. PMID: 12743156

10. Bacci G, Rocca M, Salone M, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol. 2008;98(6):415-420. PMID: 18668637

11. Patel SR, Benjamin RS. Role of growth factors in osteosarcoma. Med Pediatr Oncol. 2000;35(6):586-588. PMID: 11107127

12. Watanabe N, Matsumoto S, Shimoji T, et al. Early evaluation of chemotherapeutic response by FDG-PET/CT predicts event-free and overall survival in patients with osteosarcoma. Nucl Med Commun. 2012;33(12):1285-1292. PMID: 23032338

13. Cesari M, Alberghini M, Vanel D, et al. Periosteal osteosarcoma: a single-institution experience. Cancer. 2011;117(8):1731-1735. PMID: 21472720

14. Rosenberg AE, Nielsen GP. Osteosarcomas. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC Press; 2013:281-295.

15. Chen X, Bahrami A, Pappo A, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 2014;7(1):104-112. PMID: 24703847

16. Gelderblom H, Jinks RC, Sydes M, et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer. 2011;47(6):895-902. PMID: 21215614

17. Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39-50. PMID: 29210294

18. Biermann JS, Chow W, Reed DR, et al. NCCN Guidelines Insights: Bone Cancer, Version 2.2017. J Natl Compr Canc Netw. 2017;15(2):155-167. PMID: 28188186

19. Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv79-iv95. PMID: 29846512

20. Stevenson JD, Laitinen MK, Parry MC, et al. The role of surgical margins in chondrosarcoma. Eur J Surg Oncol. 2018;44(9):1412-1418. PMID: 29803415

21. Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J Pediatr Hematol Oncol. 2008;30(6):425-430. PMID: 18525458

22. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9(4):422-441. PMID: 15266096